In 2009, a new strain of influenza A, H1N1, began to spread across the world, reaching pandemic status in months. Widespread vaccination was necessary. As vaccine rollout progressed, experts from regulatory agencies, vaccine manufacturing companies, public health institutes, universities, and other stakeholder groups began to call for the creation of an ecosystem for rapid and robust monitoring of vaccine coverage, benefits, and risks to better prepare for future pandemics.
IMI project ADVANCE was a public-private partnership with the primary objective of creatingthis ecosystem. Among many other outputs, the ADVANCE consortium produced a robust code of conduct and governance for conducting collaborative vaccine studies on coverage, effectiveness, safety and benefit-risk. The project concluded in April of 2019. Eight months later the Vaccine Monitoring Collaboration for Europe (VAC4EU) was signed into existence as a non-profit international association as a sustainability solution to ADVANCE. The mission of VAC4EU was to continue this valuable work, just in time for another pandemic…
Outputs from ADVANCE
Throughout its duration, ADVANCE generated a wealth of knowledge and practical tools for vaccine benefit-risk assessment. Explore the project’s outputs below, including publications, deliverables, webinars, and other materials.
-
List of study needs and framework requirements draft R Month 61.01
-
List of topics for proof-of-concept studies Ph I R Month 61.02
-
Final report on existing models of public-private interactions R Month 91.03
-
Analysis of public concerns and perceptions related to benefits and risks of vaccines R Month 121.04
-
Initial conceptual model for public-private interaction R Month 151.05
-
Guidance on best practices draft P Month 181.06
-
Conference "EU ecosystem for monitoring of post-licensure vaccine benefit and risk: From ADVANCE to VAC4EU"6 March 2019
-
Interactive dashboard to monitor vaccine benefit and risk
-
Interactive dashboard to monitor vaccine benefit and risk